Dr. Benjamin Nathaniel Lockshin, MD

Dr. Lockshin practices at Foot and Ankle Center at the Burkland Medical Center - Surgery Center in Silver Spring, Maryland.

Dr. Lockshin's NPI, 1275523110, was assigned on October 23, 2005. Dr. Lockshin graduated from Georgetown University School of Medicine in 2001. Dr. Lockshin holds Maryland license D0063751.

Dr. Lockshin's primary practice is Foot and Ankle Center at the Burkland Medical Center - Surgery Center, at 10313 Georgia Avenue, Suite 201, Silver Spring, MD 20902. The practice phone is (301) 592-0505.

Dr. Lockshin's primary practice is Foot and Ankle Center at the Burkland Medical Center - Surgery Center in Silver Spring, Maryland. The medical group on file is U.S. Dermatology Partners Silver Spring. Dmand AI also links Dr. Lockshin to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lockshin practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Lockshin's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dmand AI has Dr. Lockshin's licenses on file in 2 states: Maryland and Ohio.

CMS data shows 5,325 Medicare services from Dr. Lockshin across 23 procedure codes in 2024, for 1,257 Medicare patients. Medicare paid $304,085 for them. Every service was in an office.

CMS counts 1,257 Medicare patients who saw Dr. Lockshin in 2024. The largest group is 75 to 84, with 535 patients. 75% of them have high cholesterol, and 69% have high blood pressure. Their average risk score is 0.90, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Lockshin's median patient age at 63, with 45% women.

In 2024, Dr. Lockshin wrote 1,149 Medicare Part D claims for 378 patients. 68% of them were for generic drugs. CMS names the drug for 994 of them, across 27 drugs with 11 or more claims each, at $1,670,639 in total drug cost. In 2023, CMS named 833 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Lockshin for performance year 2024, reported as part of a group. Dr. Lockshin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 1,335 procedures of removal of skin lesions by Dr. Lockshin, more than 95% of the clinicians it reports for that procedure.

Dmand AI links 38 papers to Dr. Lockshin, published from 2013 to 2025. 2016 was the busiest year, with 3. The most frequent topics are Psoriasis, Dermatitis, Atopic and Double-Blind Method. Dr. Lockshin has published most often in J Am Acad Dermatol. Dr. Lockshin's most frequent co-authors are Nehal N. Mehta, MD, Joel M. Gelfand, MD and David Alan Bluemke, MD.

Dmand AI links Dr. Lockshin to 20 clinical trials, 3 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Dermatitis, Atopic, Eczema and Psoriasis. Eli Lilly and Company sponsors the most, 10. Open Payments lists research payments to Dr. Lockshin that name 14 trials.

CMS Open Payments shows 5,403 general payments to Dr. Lockshin from 46 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 73% of the total. Abbvie Inc. paid the most, $1,010,953. It also lists 151 research payments totaling $225,748 from 2016 to 2025, naming 14 clinical trials.

Dr. Lockshin graduated from Georgetown University School of Medicine in 2001.